MX2013003662A - Metodos y composiciones para diagnostico y pronostico de lesion renal e insuficiencia renal. - Google Patents

Metodos y composiciones para diagnostico y pronostico de lesion renal e insuficiencia renal.

Info

Publication number
MX2013003662A
MX2013003662A MX2013003662A MX2013003662A MX2013003662A MX 2013003662 A MX2013003662 A MX 2013003662A MX 2013003662 A MX2013003662 A MX 2013003662A MX 2013003662 A MX2013003662 A MX 2013003662A MX 2013003662 A MX2013003662 A MX 2013003662A
Authority
MX
Mexico
Prior art keywords
peptide
renal
prognosis
diagnosis
compositions
Prior art date
Application number
MX2013003662A
Other languages
English (en)
Inventor
Joseph Anderberg
Jeff Gray
Paul Mcpherson
Kevin Nakamura
James Patrick Kampf
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of MX2013003662A publication Critical patent/MX2013003662A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con métodos y composiciones para monitorear, diagnóstico, pronóstico y determinación de regímenes de tratamiento en sujetos que sospechan que tienen una lesión renal. En particular, la invención se relaciona con el uso de pruebas que detectan uno o más marcadores seleccionados del grupo que consiste de factor de crecimiento Beta-nervio, Interleucina-17A, beta subunidad Folintropina, Colagenasa 3, Foliestatina, Proteína de Enlace Vitamina D, polipéptido amiloide de Islote, péptido C de Insulina, Factor H de Complemento, polipéptido inhibitorio Gástrico, péptido 1 similar al Glucagón, Glucagón, Involucrina, Queratiria-1/Queratina-10 citoqueletal Tipo II, Queratina citosqueletal Tipo II-6A/6B/6C, Osteocalcina, Lipopolisacarido, pro-hormona pancreática, Péptido YY, proteína relacionada con Agouti, factor neurotrófico ciliar, hormona regulatoria del Apetito, Transtiretina, sustrato 1 receptor de Insulina, e inhibidor alfa NF-kappa-B como pruebas de biomarcadores de diagnóstico y pronóstico en lesiones renales.
MX2013003662A 2010-10-07 2011-10-06 Metodos y composiciones para diagnostico y pronostico de lesion renal e insuficiencia renal. MX2013003662A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39099910P 2010-10-07 2010-10-07
PCT/US2011/055055 WO2012048082A2 (en) 2010-10-07 2011-10-06 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
MX2013003662A true MX2013003662A (es) 2013-05-01

Family

ID=45928428

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003662A MX2013003662A (es) 2010-10-07 2011-10-06 Metodos y composiciones para diagnostico y pronostico de lesion renal e insuficiencia renal.

Country Status (12)

Country Link
US (1) US20130316370A1 (es)
EP (2) EP3249402A1 (es)
JP (3) JP2013539861A (es)
CN (1) CN103238068B (es)
AU (1) AU2011311997A1 (es)
CA (1) CA2811438A1 (es)
EA (1) EA201390293A1 (es)
HK (1) HK1186248A1 (es)
IN (1) IN2013MN00441A (es)
MX (1) MX2013003662A (es)
NZ (1) NZ608316A (es)
WO (1) WO2012048082A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015042465A1 (en) * 2013-09-20 2015-03-26 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
AU2015220754A1 (en) 2014-02-20 2016-08-25 Immundiagnostik Ag In vitro diagnostic and prognosis of contrast induced nephropathy (CIN) in patients undergoing coronary angiography
CA2988980A1 (en) * 2015-06-11 2016-12-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN106405064B (zh) * 2016-08-30 2018-10-26 嘉兴行健生物科技有限公司 一种40岁以上女性骨转换率的评估方法
EP3626734A4 (en) * 2017-03-16 2020-12-02 Shenzhen Institutes of Advanced Technology POLYPEPTIDE FOR REGULATING ENERGY METABOLISM AND USES THEREOF
CN109468357A (zh) * 2018-12-25 2019-03-15 河北肽都生物科技有限公司 一种脾氨肽的制备方法
WO2021018774A1 (en) * 2019-07-26 2021-02-04 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Ergothioneine, s-methyl-ergothioneine, and uses thereof
CN113092768A (zh) * 2019-12-23 2021-07-09 首都医科大学附属北京世纪坛医院 尿液角蛋白,ii型细胞骨架1及其多肽片段在过敏性疾病中的应用
CN114264828B (zh) * 2022-01-28 2023-09-08 中国科学院基础医学与肿瘤研究所(筹) 鉴别良性甲状腺结节与甲状腺癌的生物标志物及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
JPH05504841A (ja) 1990-09-14 1993-07-22 バイオサイト・ダイアグノスティックス・インコーポレイテッド リガンドレセプター及びリガンドのコンプレックスに対する抗体及びリガンド―レセプターアッセーでのそれらの用途
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
ES2150915T3 (es) 1991-04-12 2000-12-16 Biosite Diagnostics Inc Nuevos conjugados y dosificados destinados para la deteccion simultanea de ligandos multiples.
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
JP4487376B2 (ja) * 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
JP2002191398A (ja) * 2000-12-26 2002-07-09 Jenokkusu Soyaku Kenkyusho:Kk アレルギー性疾患検査方法
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20030224386A1 (en) * 2001-12-19 2003-12-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
WO2005000194A2 (en) * 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
US6941172B2 (en) * 2002-11-18 2005-09-06 Zvi Nachum Method and device for restoring kidney function using electromagnetic stimulation
AU2005233212A1 (en) * 2004-04-16 2005-10-27 Monash University A method for monitoring the progress of cancer
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
FR2872579B1 (fr) * 2004-06-30 2006-11-24 Pasteur Institut Detection de la tuberculose et de l'infection par mycobacterium tuberculosis a l'aide de hbha
DE602005023216D1 (de) * 2004-12-15 2010-10-07 Beth Israel Hospital Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen
ES2622467T3 (es) * 2004-12-20 2017-07-06 Antibodyshop A/S Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales
US20070087387A1 (en) * 2005-04-21 2007-04-19 Prasad Devarajan Method for the Early Detection of Renal Disease Using Proteomics
JP2007057509A (ja) * 2005-08-26 2007-03-08 Toray Ind Inc ネコアクチビンａの測定方法およびその測定キット
WO2007106781A2 (en) * 2006-03-10 2007-09-20 University Of Rochester Ecg-based differentiation of lqt1 and lqt2 mutation
WO2007109809A1 (en) * 2006-03-23 2007-09-27 Invitrogen Corporation Methods and reagents for in vivo imaging of cancer cell lines
US7662578B2 (en) * 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
US20090047694A1 (en) * 2007-08-17 2009-02-19 Shuber Anthony P Clinical Intervention Directed Diagnostic Methods
SI2125899T1 (sl) * 2007-03-26 2013-02-28 Novartis Ag Napovedni renalni varnostni biomarkerji in biomarkerske signature za monitoring delovanja ledvic
US9091695B2 (en) * 2007-06-01 2015-07-28 Laboratory Corporation Of America Holdings Methods and systems for quantification of peptides and other analytes
EP2203743A4 (en) * 2007-09-20 2011-03-02 Univ Louisville Res Found PEPTIDE BIOMARKER FOR PREDICTING WEARNING OF THE KIDNEY FUNCTION AND A CHILDNESS
US7977110B2 (en) * 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
WO2010057184A2 (en) * 2008-11-17 2010-05-20 The Brigham And Women's Hospital, Inc. Methods for detection of acute kidney injury in humans
CN102272328B (zh) * 2008-11-22 2014-06-18 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
JP5981144B2 (ja) * 2009-02-06 2016-08-31 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断
NZ601575A (en) * 2009-02-06 2014-08-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and failure
CA2790785A1 (en) * 2010-02-26 2011-09-01 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Also Published As

Publication number Publication date
WO2012048082A3 (en) 2012-06-21
WO2012048082A2 (en) 2012-04-12
EA201390293A1 (ru) 2013-09-30
JP6321080B2 (ja) 2018-05-09
EP2625524A2 (en) 2013-08-14
HK1186248A1 (zh) 2014-03-07
JP2013539861A (ja) 2013-10-28
EP2625524A4 (en) 2014-05-07
CA2811438A1 (en) 2012-04-12
AU2011311997A1 (en) 2013-04-04
CN103238068A (zh) 2013-08-07
EP3249402A1 (en) 2017-11-29
US20130316370A1 (en) 2013-11-28
JP2016180762A (ja) 2016-10-13
IN2013MN00441A (es) 2015-05-29
JP2018141793A (ja) 2018-09-13
CN103238068B (zh) 2016-06-08
NZ608316A (en) 2015-03-27

Similar Documents

Publication Publication Date Title
MX2013003662A (es) Metodos y composiciones para diagnostico y pronostico de lesion renal e insuficiencia renal.
PH12017501252A1 (en) Gip and glp-1 co-agonist compounds.
Pala et al. Relationship between GLP‐1 levels and dipeptidyl peptidase‐4 activity in different glucose tolerance conditions
WO2008061149A3 (en) Methods and compositions for diagnosis and prognosis of renal artery stenosis
Yabe et al. Little enhancement of meal‐induced glucagon‐like peptide 1 secretion in Japanese: comparison of type 2 diabetes patients and healthy controls
WO2008084331A3 (en) Biomarkers for renal disorders
BRPI0716811B8 (pt) anticorpos antirreceptor alfa de folato humano,usos e método de produção dos mesmos, coquetel dos mesmos, vetor de expressão, microrganismo hospedeiro, composição e combinação farmacêuticas, e método para o diagnóstico ou reprodução de imagens de carcinoma ovariano ou suas metástases
IN2012DN01322A (es)
WO2012170438A3 (en) HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO A COMPLEX COMPRISING β-KLOTHO AND AN FGF RECEPTOR
WO2009101059A3 (en) Methods of using cadherin 11 (cdh11) antagonists
MX2009011007A (es) Biomarcadores para esclerosis multiple.
UA96139C2 (uk) Антитіло до нейропіліну-1 (nrp1)
GB0510511D0 (en) Diagnosis of tuberculosis
BR112012007365A2 (pt) proteínas de ligação à il-1
TN2012000268A1 (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
MX336280B (es) Metodos y composiciones para diagnosticos y pronosticos de lesion renal y falla renal.
Reid et al. The effect of bariatric surgery on renal function
WO2008144761A3 (en) Methods and compositions for identifying and treating lupus
CL2007003513A1 (es) Kit para la deteccion de un peptido diana seleccionado del grupo del peptido beta-amiloide (ab) ab42, ab40 y la combinacion de ambos; y su uso para el diagnostico de un trastorno degenerativo en un sujeto.
Sillakivi et al. Plasma levels of gastric biomarkers in patients after bariatric surgery: biomarkers after bariatric surgery.
Liu et al. Ageing and type 2 diabetes in an elderly Chinese population: the role of insulin resistance and beta cell dysfunction
Svatetz et al. Obesity and cancer:“Dangerous friendship”
Wang et al. Profiling analysis reveals the potential contribution of peptides to human adipocyte differentiation
Mulukutla et al. Elevated unmethylated and methylated insulin DNA are unique markers of A+ β+ ketosis prone diabetes
Nishi et al. Laboratory and imaging features of kidney involvement in autoimmune pancreatitis: incidence, correlation, and steroid therapy response.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal